Changes in <i>SLC2A2</i> gene expression in hepatocellular carcinoma (HCC) based on its stage and correlation with oncofetal and stemness genes. by Yejin Kim (740789)

Subjects:

<i>SLC2A2</i> is essential for liver differentiation in developing vertebrates by Yejin Kim (740789)

Subjects:

The wound appearance of different groups during the period of study (a) and the percentage of wound reduction in treated groups on different days (b). by Omid Mehrpour (9385929)

Serum concentrations of malondialdehyde (a) and super oxide dismutase (b) and NOx (nitrate +nitrite) (c) in different experimental groups on day 2 and 10. by Omid Mehrpour (9385929)

PDRN decreases the expression of cellular aging markers. by Jingjing Chen (293564)

The concentration of inflammatory parameters (TNF-α and IL-10) in serum (a and b) and burned skin samples (c) of different experimental groups on day 2 and 10. by Omid Mehrpour (9385929)

The concentrations of malondialdehyde (a), super oxide dismutase (b), and NOx (nitrate +nitrite)(c) in the burned skin samples of different experimental groups on day 2 and 10. by Omid Mehrpour (9385929)

Renal (urea and creatinine) (a, b) and Liver function (ALT and AST) (c, d) test in serums of different experimental groups and body weight changes (e) on day 10. by Omid Mehrpour (9385929)

Cephalometric measurement points. by Lijuan Liu (136685)

Changes in baseline T-cell activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

(A) Auxiliary marking points to ensure complete and accurate seating of the prosthesis. by Long Li (6555)

Changes in baseline T-cell exhaustion, monocyte activation and platelet activation markers through week 12 and week 24 according to the linear regression model. a. by Tosi M. Mwakyandile (16408705)

Guidelines and policy changes for different alert levels in Gauteng. The time intervals are separated by points of inflection identified in Edholm <i>et al</i>. [10]; these points... by Folashade B. Agusto (3663010)

“…[<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0325619#pone.0325619.ref010" target="_blank">10</a>]; these points separate time periods where the rate of cumulative cases was increasing from periods when the rate of cumulative cases was decreasing [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0325619#pone.0325619.ref010" target="_blank">10</a>], Fig 1]. …”

Changes in AL (A) and SE (B) according to the treatment time estimation curve in patients given 0.125% atropine. by Zi-Rong Chen (9227618)

“…<p><b>(A)</b> The crucial period and outcome measurement period in the current study. …”

Processing of wakefulness and sleep EEG data to calculate the HFD in a representative subject. by Francesco Colussi (22421582)

Validation of genetic markers for risk of OA or knee OA for decrease in minJSW. by Mieke L. M. Bentvelzen (21594442)

Comparison between fitted model (solid lines) and data (markers) at the whole lung scale (a) and in the same three example grids as Fig 2b. by Monica E. Shapiro (22622240)

Selection of soil particle sampling points. by Xueting Ma (390540)

Relationship between the Gender Representation Disparity Index (GRDI) and average explicit sex markers in film criticism, illustrating a decrease in markers as the GRDI moves toward a female-dominated cast. by Jad Doughman (20636304)

“…<p>Relationship between the Gender Representation Disparity Index (GRDI) and average explicit sex markers in film criticism, illustrating a decrease in markers as the GRDI moves toward a female-dominated cast.…”

Comparison of serum VEGF-A165 concentrations pre-bevacizumab administration in patients with increased VEGF-A post-bevacizumab administration and those with decreased VEGF-A. by Masashi Okawa (8951294)

Subjects: